OBSOLETE: Primary pigmented nodular adrenocortical disease Advocacy Hub | UniteRare

At a Glance

Live from database

💊

2FDA treatments

Regulatory Watchboard

No FDA or trial events recorded yet for OBSOLETE: Primary pigmented nodular adrenocortical disease.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for OBSOLETE: Primary pigmented nodular adrenocortical disease.
Check the disease page for updates →

Approved Treatments

2 FDA-approved

Sunosi

(Solriamfetol)Orphan drugstandard

Axsome Malta, Ltd.

Dopamine and Norepinephrine Reuptake Inhibitor [EPC]

12.1 Mechanism of Action The mechanism of action of solriamfetol to improve wakefulness in patients with excessive daytime sleepiness associated with ...

FDA label ↗

Provigil

(Modafinil)Orphan drugstandard

Cephalon, Inc.

Sympathomimetic-like Agent [EPC]

12.1 Mechanism of Action The mechanism(s) through which modafinil promotes wakefulness is unknown. Modafinil has wake-promoting actions similar to sym...

FDA label ↗

View full treatment details on disease page →